{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:46:25Z","timestamp":1768484785761,"version":"3.49.0"},"reference-count":25,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2013,8,14]]},"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>In 2010, the European Society of Gastrointestinal Endoscopy delivered guidelines on the prophylaxis of postendoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis (PEP). These included Grade A recommendations advising the use of prophylactic pancreatic stent (PPS) and non-steroidal anti-inflammatory drugs (NSAIDs) in high-risk cases. Our study aim was to capture the current practice of UK biliary endoscopists in the prevention of PEP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>In summer 2012, an anonymous online 15-item survey was emailed to 373 UK consultant gastroenterologists, gastrointestinal surgeons and radiologists identified to perform ERCP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The response rate was 59.5% (222\/373). Of the respondents, 52.5% considered ever using PPS for the prevention of PEP. PPS users always attempted insertion for the following procedural risk factors: pancreatic sphincterotomy (48.9%), suspected sphincter of Oddi dysfunction (46.5%), pancreatic duct instrumentation (35.9%), previous PEP (25.2%), precut sphincterotomy (8.5%) and pancreatic duct injection (7.8%). Prophylactic NSAID use was significantly associated with attempts at PPS placement (p&lt;0.001). 64.1% of non-PPS users cited a lack of conviction in their benefit as the main reason for their decision. Self-reported pharmacological use rates for PEP prevention were: NSAIDs (34.6%), antibiotics (20.6%), rapid intravenous fluids (13.2%) and octreotide (1.6%). 6% routinely measured amylase post-ERCP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Despite strong evidence-based guidelines for prevention of PEP, less than 53% of ERCP practitioners use pancreatic stenting or NSAIDs. This suggests a need for the development of British Society of Gastroenterology guidelines to increase awareness in the UK. Even among stent users, PPS are being underused for most high-risk cases. Prophylactic pharmacological measures were rarely used as was routine post-ERCP serum amylase measurement.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/flgastro-2013-100323","type":"journal-article","created":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T00:41:55Z","timestamp":1378255315000},"page":"103-110","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["UK wide survey on the prevention of post-ERCP pancreatitis"],"prefix":"10.1136","volume":"5","author":[{"given":"Mina S","family":"Hanna","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Bristol Royal Infirmary, University Hospitals Bristol NHS Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J","family":"Portal","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Bristol Royal Infirmary, University Hospitals Bristol NHS Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin D","family":"Dhanda","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Przemioslo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Frenchay Hospital, North Bristol NHS Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,9,3]]},"reference":[{"key":"2025090708462198000_5.2.103.1","doi-asserted-by":"crossref","unstructured":"Andriulli A Loperfido S Napolitano G . Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007;(102):1781\u20138.","DOI":"10.1111\/j.1572-0241.2007.01279.x"},{"key":"2025090708462198000_5.2.103.2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-42614"},{"key":"2025090708462198000_5.2.103.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00380.x"},{"key":"2025090708462198000_5.2.103.4","doi-asserted-by":"publisher","DOI":"10.1067\/mge.2001.117550"},{"key":"2025090708462198000_5.2.103.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(04)02013-9"},{"key":"2025090708462198000_5.2.103.6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.gie.2010.10.039","article-title":"Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review","volume":"73","author":"Choudhary","year":"2011","journal-title":"Gastrointest Endosc"},{"key":"2025090708462198000_5.2.103.7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.140756"},{"key":"2025090708462198000_5.2.103.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111103"},{"key":"2025090708462198000_5.2.103.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2006.01.058"},{"key":"2025090708462198000_5.2.103.10","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.gie.2009.10.055","article-title":"Prophylaxis of post-ERCP pancreatitis: a practice survey","volume":"71","author":"Dumonceau","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"2025090708462198000_5.2.103.11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1055\/s-0029-1244208","article-title":"European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis","volume":"42","author":"Dumonceau","year":"2010","journal-title":"Endoscopy"},{"key":"2025090708462198000_5.2.103.12","first-page":"251","article-title":"Prophylactic Pancreatic Duct Stents","volume":"4","author":"Elta","year":"2008","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"2025090708462198000_5.2.103.13","doi-asserted-by":"crossref","first-page":"796751","DOI":"10.1155\/2012\/796751","article-title":"Prevention of post-ERCP pancreatitis","volume":"2012","author":"Donnellan","year":"2012","journal-title":"Gastroenterol Res Pract"},{"key":"2025090708462198000_5.2.103.14","first-page":"A413","article-title":"Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy (ES)-induced pancreatitis? A final analysis of a randomized prospective study","volume":"43","author":"Sherman","year":"1996","journal-title":"Gastrointestinal Endosc"},{"key":"2025090708462198000_5.2.103.15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.cgh.2009.05.002","article-title":"Short 5Fr vs long 3Fr pancreatic stents in patients at high risk for post- endoscopic cholangiopancreatography pancreatitis","volume":"7","author":"Chahal","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090708462198000_5.2.103.16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1155\/2011\/678540","article-title":"Moderate and severe post-ERCP pancreatitis despite prophylactic pancreatic stent placement. The effect of early prophylactic pancreatic stent dislodgement","volume":"25","author":"Moffatt","year":"2011","journal-title":"Can J Gastroenterol"},{"key":"2025090708462198000_5.2.103.17","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.gie.2011.01.012","article-title":"Acute pancreatitis after removal of retained prophylactic pancreatic stents","volume":"73","author":"Moffatt","year":"2011","journal-title":"Gastrointest Endosc"},{"key":"2025090708462198000_5.2.103.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(96)70164-5"},{"key":"2025090708462198000_5.2.103.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(96)70163-3"},{"key":"2025090708462198000_5.2.103.20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1046\/j.1440-1746.2001.02547.x","article-title":"Prediction of pancreatitis following endoscopic retrograde cholangiopancreatography by the 4-h post procedure amylase level","volume":"16","author":"Thomas","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"2025090708462198000_5.2.103.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.09.007"},{"key":"2025090708462198000_5.2.103.22","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.gie.2012.08.021","article-title":"Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis","volume":"76","author":"Ding","year":"2012","journal-title":"Gastrointest Endosc"},{"key":"2025090708462198000_5.2.103.23","doi-asserted-by":"crossref","unstructured":"Mazaki T Mado K Masuda H . Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. J Gastroenterol 2013. [Epub ahead of print].","DOI":"10.1007\/s00535-013-0806-1"},{"key":"2025090708462198000_5.2.103.24","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.cgh.2012.12.043","article-title":"Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis","volume":"11","author":"Akbar","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090708462198000_5.2.103.25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ajg.2012.442","article-title":"Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data","volume":"108","author":"Elmunzer","year":"2013","journal-title":"Am J Gastroenterol"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2013-100323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:46:30Z","timestamp":1757259990000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2013-100323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,3]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,28]]},"published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1136\/flgastro-2013-100323"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2013-100323","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,3]]}}}